US PTO agrees to reissue '995 Lipitor enantiomer patent
This article was originally published in Scrip
The US Patent and Trademark Officehas agreed to accept Pfizer's application to correct the technical defect in the '995 enantiomer patent covering atorvastatin calcium, the salt form sold as Lipitor (expiring in June 2011). The Court of Appeals for the Federal Circuit ruled in August 2006 that the patent was "invalid on technical grounds", but Pfizervowed to have that decision overturned by working with the PTO on the process for correcting such defects.
You may also be interested in...
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.